OmniCorder Technologies, Inc. (OTCBB Symbol: OMCT) today announced the delivery of a new cancer therapy monitoring configuration of its BioScanIR(R) System to The Cleveland Clinic. The system will be used to detect the effects of cancer treatments in patients undergoing neoadjuvant breast cancer therapy as part of a collaboration between OmniCorder Technologies and the Case Comprehensive Cancer Center, which includes The Cleveland Clinic Taussig Cancer Center and Case Western Reserve University School of Medicine.
